search
Back to results

Efficacy and Safety of Hydromorphone-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia

Primary Purpose

Analgesia, Labor Pain

Status
Not yet recruiting
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
Hydromorphone
Sufentanil
Ropivacaine
Sponsored by
Maternal and Child Health Hospital of Hubei Province
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Analgesia

Eligibility Criteria

20 Years - 40 Years (Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: American Society of Anesthesiologists (ASA) physical status II a single fetus competent to provide informed consent Exclusion Criteria: severe respiratory diseases including hypoxemia, respiratory failure and severe pneumonia severe circulatory diseases including acute decompensated heart failure and peripartum cardiomyopathy placenta previa

Sites / Locations

  • Maternal and Child Health Hospital of Hubei Province

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Arm Label

Group 1

Group 2

Group 3

Group 4

Arm Description

Group 1 will be administered with 15 ug/ml hydromorphone and 0.08% ropivacaine

Group 2 will be administered with 17.5 ug/ml hydromorphone and 0.08% ropivacaine

Group 3 will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine

Group 4 will be administered with 0.4 ug/ml sufentanil and 0.08% ropivacaine

Outcomes

Primary Outcome Measures

Visual Analogue Scale(VAS)
VAS will be monitored and recorded at 6 time points, including the time of entering the operating room(Time 0), when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), when the first dose is given for 30 minutes(Time 3), 30 minutes after delivery (Time 4), and 60 minutes after delivery (Time 5). The VAS consists of a 10 cm line, with two end points representing 0 (no pain) and 10 (pain as bad as it could possibly be).

Secondary Outcome Measures

Heart rate(HR)
HR will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4).
Mean arterial pressure(MAP)
MAP will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4).
Pulse oxygen saturation
Pulse oxygen saturation will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4).
Duration of analgesia
Defined as the time from labor analgesia to delivery of the fetus.
The number of compressions
The number of compressions by electronic analgesia pump from labor analgesia to delivery of the fetus.
Adverse reactions
The occurrence of adverse reactions(nausea, vomiting, skin itching and other adverse reactions).
The Apgar scores
The Apgar scores of 1 minute and 5 minutes after birth will be recorded.

Full Information

First Posted
September 7, 2023
Last Updated
September 7, 2023
Sponsor
Maternal and Child Health Hospital of Hubei Province
search

1. Study Identification

Unique Protocol Identification Number
NCT06036797
Brief Title
Efficacy and Safety of Hydromorphone-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia
Official Title
Efficacy and Safety of Hydromorphone-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia: a Randomized Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 17, 2023 (Anticipated)
Primary Completion Date
October 17, 2023 (Anticipated)
Study Completion Date
October 17, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Maternal and Child Health Hospital of Hubei Province

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
The purpose of this study is to compare the effects of three different doses of hydromorphone combined with ropivacaine and sufentanil combined with ropivacaine in epidural labor analgesia through prospective clinical trials, so as to explore whether hydromorphone combined with ropivacaine has advantages in epidural labor analgesia, and find out the optimal dose of hydromorphone. Participants will be randomly allocated to four groups : Group 1, Group 2, Group 3 and Group 4. For those in Group 1 : they will be administered with 15 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in Group 2 : they will be administered with17.5 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil and 0.08% ropivacaine for epidural labor analgesia. The goal of this clinical trial is to provide a new treatment option for pregnant women in epidural labor analgesia, and to provide a basis for hydromorphone combined with ropivacaine in epidural labor analgesia.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Analgesia, Labor Pain

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
240 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group 1
Arm Type
Experimental
Arm Description
Group 1 will be administered with 15 ug/ml hydromorphone and 0.08% ropivacaine
Arm Title
Group 2
Arm Type
Experimental
Arm Description
Group 2 will be administered with 17.5 ug/ml hydromorphone and 0.08% ropivacaine
Arm Title
Group 3
Arm Type
Experimental
Arm Description
Group 3 will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine
Arm Title
Group 4
Arm Type
Active Comparator
Arm Description
Group 4 will be administered with 0.4 ug/ml sufentanil and 0.08% ropivacaine
Intervention Type
Drug
Intervention Name(s)
Hydromorphone
Intervention Description
For those in Group 1 : they will be administered with 15 ug/ml hydromorphone, For those in Group 2 : they will be administered with 17.5 ug/ml hydromorphone, For those in Group 3 : they will be administered with 20 ug/ml hydromorphone
Intervention Type
Drug
Intervention Name(s)
Sufentanil
Intervention Description
For those in Group 4 : they will be administered with 0.4 ug/ml sufentanil
Intervention Type
Drug
Intervention Name(s)
Ropivacaine
Intervention Description
0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms
Primary Outcome Measure Information:
Title
Visual Analogue Scale(VAS)
Description
VAS will be monitored and recorded at 6 time points, including the time of entering the operating room(Time 0), when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), when the first dose is given for 30 minutes(Time 3), 30 minutes after delivery (Time 4), and 60 minutes after delivery (Time 5). The VAS consists of a 10 cm line, with two end points representing 0 (no pain) and 10 (pain as bad as it could possibly be).
Time Frame
30 minutes-1 hour
Secondary Outcome Measure Information:
Title
Heart rate(HR)
Description
HR will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4).
Time Frame
30 minutes-1.5 hours
Title
Mean arterial pressure(MAP)
Description
MAP will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4).
Time Frame
30 minutes-1.5 hours
Title
Pulse oxygen saturation
Description
Pulse oxygen saturation will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4).
Time Frame
30 minutes-1.5 hours
Title
Duration of analgesia
Description
Defined as the time from labor analgesia to delivery of the fetus.
Time Frame
30 minutes-1.5 hours
Title
The number of compressions
Description
The number of compressions by electronic analgesia pump from labor analgesia to delivery of the fetus.
Time Frame
30 minutes-1.5 hours
Title
Adverse reactions
Description
The occurrence of adverse reactions(nausea, vomiting, skin itching and other adverse reactions).
Time Frame
30 minutes-1.5 hours
Title
The Apgar scores
Description
The Apgar scores of 1 minute and 5 minutes after birth will be recorded.
Time Frame
1 minute and 5 minutes after birth

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: American Society of Anesthesiologists (ASA) physical status II a single fetus competent to provide informed consent Exclusion Criteria: severe respiratory diseases including hypoxemia, respiratory failure and severe pneumonia severe circulatory diseases including acute decompensated heart failure and peripartum cardiomyopathy placenta previa
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Na Li, MD
Phone
+862763490107
Email
lina@hbfy.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Na Li, MD
Organizational Affiliation
Maternal and Child Health Hospital of Hubei Province
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maternal and Child Health Hospital of Hubei Province
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430000
Country
China

12. IPD Sharing Statement

Learn more about this trial

Efficacy and Safety of Hydromorphone-ropivacaine Versus Sufentanil-ropivacaine for Epidural Labor Analgesia

We'll reach out to this number within 24 hrs